Enkeltsidet døvhed i Medicare-befolkningen
Cochlear implantation i enkeltsidet døvhed i Medicare-populationen
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
-
-
Iowa
-
Iowa City, Iowa, Forenede Stater, 52242
- University of Iowa Hospitals and Clinics
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27599
- University of North Carolina
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Beskrivelse
Inklusionskriterier:
- 65 år eller ældre på tidspunktet for implantation
- Ensidigt dybt høretab, som defineret ved et rent tonegennemsnit (500, 1000, 2000 og 4000 Hz) på 90 dB eller mere i øret, der skal implanteres
- Sensorineuralt høretab i øret, der skal implanteres, som defineret ved et luft-knoglegab mindre end eller lig med 10 dB ved to eller flere frekvenser ud af 500, 1000, 2000 og 4000 Hz
- Normal eller næsten normal hørelse i det ikke-implanterede øre, som defineret ved et rent tonegennemsnit (500, 1000, 2000 og 4000 Hz) på 30 dB eller mindre
- Ordgenkendelse i øret, der skal implanteres på 5 % eller mindre på CNC-ordscore i ro
- Tidligere erfaring med et passende tilpasset CROS, BI-CROS, knogleledning eller traditionelt høreapparat, som efterforskeren anser for passende
- Flydende engelsk
Ekskluderingskriterier:
- Varighed af alvorligt høretab på 10 år eller mere
- Pludselig opstået høretab inden for seks måneder efter implantation
- Bevis på ikke-funktionel cochlear nerve eller andet retrocochleært høretab
- Bevis på alvorlig cochleær misdannelse (dvs. almindelig hulrum eller ossifikation)
- Ekstern eller mellemørebetændelse
- Mistænkt kognitiv bekymring
- Anden medicinsk kontraindikation for operation eller bedøvelse
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Andet: Studieprocedure
|
Cochlear implantat og lydprocessor
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Performance of the Cochlear Implant System Will be Assessed Through Speech Perception Testing in Noise Completed Through One Year (12 Months) Post Activation.
Tidsramme: One year (12 months) post activation
|
The primary effectiveness endpoint will be change on speech in noise when speech is presented to the front and noise is presented to the acoustic hearing (contralateral) ear.
AzBio sentences in noise will be administered at 60 dB SPL with a signal-to-noise ratio of 0 dB SNR.
Pre-operatively, sentence testing will occur with a CROS hearing aid.
The pre-operative, best aided score will be compared to the 6-month and 12-month CI score for AzBio sentences in noise.
AzBio sentences in noise are scored as a percentage of words correctly repeated back out of the total number of words presented on the list (range of score 0-100, higher score is better).
Improvement is defined as greater than or equal to 10 percentage points.
|
One year (12 months) post activation
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Performance of the Cochlear Implant System Will be Summarized Through Speech Perception Testing in Noise Completed Through One Year (12 Months) Post Implantation.
Tidsramme: One year (12 months) post implantation
|
Speech in noise in two spatial conditions will demonstrate similar performance from the pre-operative, best-aided score to the CI score at 6- and 12-months post activation.
AzBio sentences in noise will be administered at 60 dB SPL with a signal-to-noise ratio of 0 dB SNR.
Pre-operatively, sentence testing will occur with a CROS hearing aid.
The pre-operative, best aided score will be compared to the 6-month and 12-month CI score for AzBio sentences in noise.
AzBio sentences in noise are scored as a percentage of words correctly repeated back out of the total number of words presented on the list (range of score 0-100, higher score is better).
Percentage point change from baseline is reported where a positive change represents an improvement from baseline and a negative change represents a decrement from baseline.
|
One year (12 months) post implantation
|
|
Performance of the Cochlear Implant System Will be Assessed Through Speech Perception Testing in Quiet Completed Through One Year (12 Months ) Post Implantation.
Tidsramme: One year (12 months) post implantation
|
Speech perception in quiet will be summarized for the CI ear at the pre-operative, 6-month, and 12-month intervals, and for the contralateral ear at the pre-operative and 12-month intervals.
One 50-word CNC Words list will be used to assess speech perception in quiet at each visit, scored as the percent of words repeated correctly out of the total words presented (range of 0-100, higher is better).
Percentage point change from baseline is reported where a positive change represents an improvement from baseline and a negative change represents a decrement from baseline.
|
One year (12 months) post implantation
|
|
Subjective Benefit of the Cochlear Implant System Will be Assessed Through One Year (12 Months) Post Implantation.
Tidsramme: One year (12 months) post implantation
|
Subjective data will be collected via the Speech, Spatial, and Qualities of Hearing Scale (SSQ).
The SSQ uses subjective responses to various questions related to speech, spatial, and other qualities of hearing reported on a Likert scale (range of score 0-10, higher score is a more positive subjective impression of ability or quality).
Responses are averaged across the entire questionnaire for the overall score and across questions related to each subscale for individual subscale scores.
Responses will be summarized from the pre-operative, 6-month, and 12-month intervals.
|
One year (12 months) post implantation
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Generelle publikationer
- Vermeire K, Van de Heyning P. Binaural hearing after cochlear implantation in subjects with unilateral sensorineural deafness and tinnitus. Audiol Neurootol. 2009;14(3):163-71. doi: 10.1159/000171478. Epub 2008 Nov 13.
- Van de Heyning P, Vermeire K, Diebl M, Nopp P, Anderson I, De Ridder D. Incapacitating unilateral tinnitus in single-sided deafness treated by cochlear implantation. Ann Otol Rhinol Laryngol. 2008 Sep;117(9):645-52. doi: 10.1177/000348940811700903.
- Arndt S, Laszig R, Aschendorff A, Hassepass F, Beck R, Wesarg T. Cochlear implant treatment of patients with single-sided deafness or asymmetric hearing loss. HNO. 2017 Aug;65(Suppl 2):98-108. doi: 10.1007/s00106-016-0297-5.
- Buss E, Dillon MT, Rooth MA, King ER, Deres EJ, Buchman CA, Pillsbury HC, Brown KD. Effects of Cochlear Implantation on Binaural Hearing in Adults With Unilateral Hearing Loss. Trends Hear. 2018 Jan-Dec;22:2331216518771173. doi: 10.1177/2331216518771173.
- Niparko JK, Cox KM, Lustig LR. Comparison of the bone anchored hearing aid implantable hearing device with contralateral routing of offside signal amplification in the rehabilitation of unilateral deafness. Otol Neurotol. 2003 Jan;24(1):73-8. doi: 10.1097/00129492-200301000-00015.
- Mertens G, De Bodt M, Van de Heyning P. Evaluation of Long-Term Cochlear Implant Use in Subjects With Acquired Unilateral Profound Hearing Loss: Focus on Binaural Auditory Outcomes. Ear Hear. 2017 Jan/Feb;38(1):117-125. doi: 10.1097/AUD.0000000000000359.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- MED-EL SSD CMS
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .